JP2013501006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501006A5 JP2013501006A5 JP2012523127A JP2012523127A JP2013501006A5 JP 2013501006 A5 JP2013501006 A5 JP 2013501006A5 JP 2012523127 A JP2012523127 A JP 2012523127A JP 2012523127 A JP2012523127 A JP 2012523127A JP 2013501006 A5 JP2013501006 A5 JP 2013501006A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 31
- 238000000034 method Methods 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 239000010681 turmeric oil Substances 0.000 claims 8
- 230000003595 spectral effect Effects 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 238000001228 spectrum Methods 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- 239000012043 crude product Substances 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 238000005576 amination reaction Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- JYODOEJCLYYBRE-TVRKMHQQSA-N (6r)-2-methyl-6-(4-methylcyclohexa-1,5-dien-1-yl)-n-(2-methylpropyl)hept-2-en-4-amine Chemical compound CC(C)CNC(C=C(C)C)C[C@@H](C)C1=CCC(C)C=C1 JYODOEJCLYYBRE-TVRKMHQQSA-N 0.000 claims 1
- MDTGNJMONJEHRU-JVWICGRDSA-N (6r)-2-methyl-6-(4-methylcyclohexa-1,5-dien-1-yl)hept-2-en-4-ol Chemical compound CC(C)=CC(O)C[C@@H](C)C1=CCC(C)C=C1 MDTGNJMONJEHRU-JVWICGRDSA-N 0.000 claims 1
- UOGAUFFBPTVCCY-DUSLRRAJSA-N (6r)-2-methyl-6-(4-methylphenyl)-n-(2-methylpropyl)hept-2-en-4-amine Chemical compound CC(C)CNC(C=C(C)C)C[C@@H](C)C1=CC=C(C)C=C1 UOGAUFFBPTVCCY-DUSLRRAJSA-N 0.000 claims 1
- JYODOEJCLYYBRE-HFCFLWKCSA-N (6s)-2-methyl-6-(4-methylcyclohexa-1,5-dien-1-yl)-n-(2-methylpropyl)hept-2-en-4-amine Chemical compound CC(C)CNC(C=C(C)C)C[C@H](C)C1=CCC(C)C=C1 JYODOEJCLYYBRE-HFCFLWKCSA-N 0.000 claims 1
- MDTGNJMONJEHRU-OWYJLGKBSA-N (6s)-2-methyl-6-(4-methylcyclohexa-1,5-dien-1-yl)hept-2-en-4-ol Chemical compound CC(C)=CC(O)C[C@H](C)C1=CCC(C)C=C1 MDTGNJMONJEHRU-OWYJLGKBSA-N 0.000 claims 1
- UOGAUFFBPTVCCY-KKFHFHRHSA-N (6s)-2-methyl-6-(4-methylphenyl)-n-(2-methylpropyl)hept-2-en-4-amine Chemical compound CC(C)CNC(C=C(C)C)C[C@H](C)C1=CC=C(C)C=C1 UOGAUFFBPTVCCY-KKFHFHRHSA-N 0.000 claims 1
- JYODOEJCLYYBRE-UHFFFAOYSA-N 2-methyl-6-(4-methylcyclohexa-1,5-dien-1-yl)-n-(2-methylpropyl)hept-2-en-4-amine Chemical compound CC(C)CNC(C=C(C)C)CC(C)C1=CCC(C)C=C1 JYODOEJCLYYBRE-UHFFFAOYSA-N 0.000 claims 1
- MDTGNJMONJEHRU-UHFFFAOYSA-N 2-methyl-6-(4-methylcyclohexa-1,5-dien-1-yl)hept-2-en-4-ol Chemical compound CC(C)=CC(O)CC(C)C1=CCC(C)C=C1 MDTGNJMONJEHRU-UHFFFAOYSA-N 0.000 claims 1
- UOGAUFFBPTVCCY-UHFFFAOYSA-N 2-methyl-6-(4-methylphenyl)-n-(2-methylpropyl)hept-2-en-4-amine Chemical compound CC(C)CNC(C=C(C)C)CC(C)C1=CC=C(C)C=C1 UOGAUFFBPTVCCY-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 230000003941 amyloidogenesis Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 208000004209 confusion Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013395 disorientation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 230000027928 long-term synaptic potentiation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 0 CC(CC(*)(*)C(*)=C(C)C)C1=CCC(*)C#C1 Chemical compound CC(CC(*)(*)C(*)=C(C)C)C1=CCC(*)C#C1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23032609P | 2009-07-31 | 2009-07-31 | |
| US61/230,326 | 2009-07-31 | ||
| US30868610P | 2010-02-26 | 2010-02-26 | |
| US61/308,686 | 2010-02-26 | ||
| PCT/US2010/044136 WO2011014880A1 (en) | 2009-07-31 | 2010-08-02 | Inhibitors of cognitive decline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501006A JP2013501006A (ja) | 2013-01-10 |
| JP2013501006A5 true JP2013501006A5 (enExample) | 2013-09-05 |
Family
ID=43529740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523127A Pending JP2013501006A (ja) | 2009-07-31 | 2010-08-02 | 認知機能低下の阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9192585B2 (enExample) |
| EP (1) | EP2458983B1 (enExample) |
| JP (1) | JP2013501006A (enExample) |
| CN (1) | CN102595884B (enExample) |
| AU (2) | AU2010278711A1 (enExample) |
| BR (1) | BR112012002246A2 (enExample) |
| DK (1) | DK2458983T3 (enExample) |
| ES (1) | ES2547730T3 (enExample) |
| IL (1) | IL217833A0 (enExample) |
| RU (1) | RU2012107457A (enExample) |
| SG (2) | SG10201506978UA (enExample) |
| WO (1) | WO2011014880A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010118055A1 (en) | 2009-04-09 | 2010-10-14 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| RU2012107457A (ru) | 2009-07-31 | 2013-09-10 | Когнишн Терапьютикс, Инк. | Ингибиторы ухудшения когнитивных способностей |
| US20130071330A1 (en) * | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| SG192596A1 (en) | 2011-02-02 | 2013-09-30 | Cognition Therapeutics Inc | Isolated compounds from turmeric oil and methods of use |
| WO2012131505A1 (en) * | 2011-03-29 | 2012-10-04 | Council Of Scientific & Industrial Research | Process for the modification of curcuma aromatica essential oil |
| GB201111319D0 (en) | 2011-07-04 | 2011-08-17 | Univ Leuven Kath | Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa |
| WO2013029057A2 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| US20140378460A1 (en) * | 2011-08-25 | 2014-12-25 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| WO2015116923A1 (en) | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| ES3063712T3 (en) | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
| WO2026030341A1 (en) | 2024-07-29 | 2026-02-05 | Cognition Therapeutics, Inc. | Zervimesine for treating neurodegenerative disease |
| WO2026136732A1 (en) | 2024-12-18 | 2026-06-25 | Cognition Therapeutics, Inc. | Compositions and methods for the treatment of dementia with lewy bodies |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| FI81713C (fi) | 1983-01-31 | 1990-12-10 | Lilly Co Eli | Foerfarande och djurfoderpremix foer befraemjande av tillvaexten, foerbaettring av utnyttjandegraden av foder eller minskning av fetthalten i koett hos ett husdjur. |
| JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| US4958029A (en) | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
| JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
| DE4142366A1 (de) * | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| AU702629B2 (en) | 1991-08-23 | 1999-02-25 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| EP1275635A1 (en) | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| JP3522930B2 (ja) * | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| US6235731B1 (en) | 1996-04-24 | 2001-05-22 | Takeda Chemical Industries, Ltd. | Fused imidazopyridine derivatives as antihyperlipidemic agents |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| AU2300001A (en) | 1999-10-22 | 2001-05-08 | Board Of Trustees Of The University Of Illinois, The | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
| WO2003016274A2 (en) | 2001-08-21 | 2003-02-27 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) * | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| UA82057C2 (en) | 2001-12-14 | 2008-03-11 | Каунсил Оф Сайентифик Энд Индастриал Рисёрч | COMPOSITION basED on AR-D-turmeron and α- anD β-turmeron FOR TREATING NEUROCEREBROVASCULAR DISORDERS |
| JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
| DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
| EP1635805A4 (en) | 2003-06-12 | 2007-08-08 | Ms Science Corp | SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT |
| SK50802006A3 (sk) | 2004-03-12 | 2007-03-01 | Egis Gy�gyszergy�r Nyrt. | Kombinovaná farmaceutická kompozícia na inhibíciupoklesu kognitívnych funkcií |
| AU2005247251A1 (en) * | 2004-05-31 | 2005-12-08 | Kaneka Corporation | Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component |
| ES2415665T3 (es) | 2004-06-21 | 2013-07-26 | Proteome Sciences Plc | Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20080153917A1 (en) | 2004-09-10 | 2008-06-26 | Ucb Pharma, S.A. | Sigma Receptor Ligands |
| US20060153772A1 (en) | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
| EP1896005A4 (en) | 2005-06-15 | 2009-11-11 | Darrick S H L Kim | SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS |
| US20070021413A1 (en) | 2005-07-20 | 2007-01-25 | Peter Herold | Diamino alcohols as therapeutic compounds |
| ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
| CA2644093A1 (en) * | 2006-03-17 | 2007-09-27 | Herbalscience Singapore Pte. Ltd. | Extracts and methods comprising curcuma species |
| US20100029654A1 (en) | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| US7723377B2 (en) * | 2006-09-29 | 2010-05-25 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| US7968524B2 (en) | 2007-05-15 | 2011-06-28 | Helicon Therapeutics, Inc. | Methods of enhancing long term memory formation by inhibition of Gpr12 |
| CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| US8168800B2 (en) | 2007-11-02 | 2012-05-01 | The Regents Of The University Of California | Aβ-binding small molecules |
| EP2138104A1 (en) | 2008-06-25 | 2009-12-30 | Vibra Tech AB | Core biopsy arrangement |
| KR101515822B1 (ko) | 2008-11-29 | 2015-04-29 | 더 타일랜드 리서치 펀드 | 바이러스와 타겟 세포의 상호작용 저해 |
| WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| JP5730280B2 (ja) | 2009-03-16 | 2015-06-03 | パング バイオファーマ リミテッド | 非カノニカル生物学的活性を有するヒスチジル−ｔＲＮＡシンテターゼスプライスバリアントを含む組成物および方法 |
| WO2010118055A1 (en) | 2009-04-09 | 2010-10-14 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| RU2012107457A (ru) * | 2009-07-31 | 2013-09-10 | Когнишн Терапьютикс, Инк. | Ингибиторы ухудшения когнитивных способностей |
| US20130071330A1 (en) | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| WO2013029057A2 (en) | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
-
2010
- 2010-08-02 RU RU2012107457/04A patent/RU2012107457A/ru not_active Application Discontinuation
- 2010-08-02 US US13/388,128 patent/US9192585B2/en active Active
- 2010-08-02 EP EP10805177.2A patent/EP2458983B1/en active Active
- 2010-08-02 SG SG10201506978UA patent/SG10201506978UA/en unknown
- 2010-08-02 AU AU2010278711A patent/AU2010278711A1/en not_active Abandoned
- 2010-08-02 DK DK10805177.2T patent/DK2458983T3/en active
- 2010-08-02 SG SG2012006805A patent/SG178191A1/en unknown
- 2010-08-02 JP JP2012523127A patent/JP2013501006A/ja active Pending
- 2010-08-02 WO PCT/US2010/044136 patent/WO2011014880A1/en not_active Ceased
- 2010-08-02 BR BR112012002246A patent/BR112012002246A2/pt not_active IP Right Cessation
- 2010-08-02 CN CN201080043697.0A patent/CN102595884B/zh not_active Expired - Fee Related
- 2010-08-02 ES ES10805177.2T patent/ES2547730T3/es active Active
-
2012
- 2012-01-30 IL IL217833A patent/IL217833A0/en unknown
-
2015
- 2015-10-12 AU AU2015242947A patent/AU2015242947B2/en not_active Ceased
- 2015-10-16 US US14/885,768 patent/US9815770B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523418A5 (enExample) | ||
| RU2012107457A (ru) | Ингибиторы ухудшения когнитивных способностей | |
| RU2011145321A (ru) | Ингибиторы снижения когнитивных способностей | |
| RU2003130268A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью | |
| WO2010000372A3 (en) | New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | |
| PH12014500392A1 (en) | Methods of synthesis and purification of heteroaryl compounds | |
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| JP2021105002A5 (enExample) | ||
| WO2010073011A3 (en) | Heterocyclic compounds and their use as ampk activators | |
| CA2456606A1 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| CA2769553A1 (en) | Novel pyrimidine and triazine hepcidin antagonists | |
| WO2009080764A3 (en) | Oral or nasal administration of compounds comprising amino acid sequences | |
| JP2014530818A5 (enExample) | ||
| JP2017537886A5 (enExample) | ||
| JP2018507230A5 (enExample) | ||
| WO2016088834A1 (ja) | ジヒドロナフタレン誘導体 | |
| JP2025111532A (ja) | ５－ブロモピリジン－３－イル－３－デオキシ－３－［４－（３，４，５－トリフルオロフェニル）－１ｈ－１，２，３－トリアゾール－１－ｙｌ］－１－チオ－アルファ－ｄ－ガラクトピラノシド及びその結晶形を調製するための大規模方法 | |
| WO2010005581A4 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) | |
| CN114072398A (zh) | 抑制tdg活性的化合物 | |
| WO2013157955A1 (en) | Geranyl geranyl acetone analogs and uses thereof | |
| TW200610754A (en) | Vla-4 inhibitor | |
| EP2772481A8 (en) | Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof | |
| CN104529724A (zh) | α-细辛醇及其制备方法与应用 | |
| WO2018233483A1 (zh) | 苯基喹啉酮类和黄酮类衍生物的制备和应用 | |
| AU2007331337A1 (en) | Aminoalcohol derivatives and their therapeutic use |